Expanded access to phase II clinical trials in oncology: A step toward increasing scientific validity and compassion

被引：0
|
作者：
Marcee, Alice K. [1 ]
机构：
[1] So Methodist Univ, Dedman Sch Law, Dallas, TX 75275 USA
来源：
FOOD AND DRUG LAW JOURNAL | 2008年 / 63卷 / 02期
关键词：
D O I：
暂无
中图分类号：
TS2 [食品工业];
学科分类号：
0832 ;
摘要：
引用
收藏
页码：439 / 457
页数：19
相关论文
共 50 条
  • [21] Precision Oncology Clinical Trials: A Systematic Review of Phase II Clinical Trials with Biomarker-Driven, Adaptive Design
    Ha, Hyerim
    Lee, Hee Yeon
    Kim, Jee Hyun
    Kim, Do Yeun
    An, Ho Jung
    Bae, SeungJin
    Park, Hye-sung
    Kang, Jin Hyoung
    CANCER RESEARCH AND TREATMENT, 2024, 56 (04): : 991 - 1013
  • [22] Economic growth of BRIC nations and access to early-phase oncology clinical trials: An overview
    Rodrigues, Heloisa Veasey
    Ganesan, Prasanth
    Liu, Xiaochun
    Subbiah, Vivek
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [23] Validity of Inclusion/Exclusion Criteria in Clinical Trials for Myelofibrosis and the Need for Expanded Access Programs [More Expanded Access Programs Are Needed to Assess the Impact of Comorbidity and Comedication in Patients with Myelofibrosis]
    Isfort, Susanne
    Jost, Edgar
    Bennemann, Karla
    Crysandt, Martina
    Akin, Sema
    Bruemmendorf, Tim H.
    Koschmieder, Steffen
    BLOOD, 2012, 120 (21)
  • [24] The phase II/III transition: Toward the proof of efficacy in cancer clinical trials
    Fazzari, M
    Heller, G
    Scher, HI
    CONTROLLED CLINICAL TRIALS, 2000, 21 (04): : 360 - 368
  • [25] Re:: Is patient travel distance associated with survival on phase II clinical trials in oncology?
    Muñoz, A
    Samet, J
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (05): : 411 - 411
  • [26] Natural Language Processing for Patient Selection in Phase I or II Oncology Clinical Trials
    Delorme, Julie
    Charvet, Valentin
    Wartelle, Muriel
    Lion, Francois
    Thuillier, Bruno
    Mercier, Sandrine
    Soria, Jean-Charles
    Azoulay, Mikael
    Besse, Benjamin
    Massard, Christophe
    Hollebecque, Antoine
    Verlingue, Loic
    JCO CLINICAL CANCER INFORMATICS, 2021, 5 : 709 - 718
  • [27] An Adaptive Design for Phase II Non-Oncology Dose Selection Clinical Trials
    Zheng Su
    Clinical Drug Investigation, 2010, 30 : 397 - 403
  • [28] Factorial clinical trials: a new approach to phase II neuro-oncology studies
    Iwamoto, Fabio M.
    Lassman, Andrew B.
    NEURO-ONCOLOGY, 2015, 17 (02) : 174 - 176
  • [29] Optimal and minimax three-stage designs for phase II oncology clinical trials
    Chen, Kun
    Shan, Michael
    CONTEMPORARY CLINICAL TRIALS, 2008, 29 (01) : 32 - 41
  • [30] Phase II clinical trials in oncology: Strengths and limitations of two-stage designs
    Schlesselman, James J.
    Reis, Isildinha M.
    CANCER INVESTIGATION, 2006, 24 (04) : 404 - 412
12345